XML 14 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Summary of Common Stock Reserved for Future Issuance

Shares of our common stock reserved for future issuance as of December 31, 2019 were as follows (in thousands):

 

 

 

Number of

 

 

 

Shares

 

Stock options outstanding

 

 

16,665

 

Stock options available for grant

 

 

4,971

 

Employee Stock Purchase Plan

 

 

370

 

Warrants outstanding

 

 

508

 

Shares of common stock underlying Convertible Notes outstanding (see Note 8)

 

 

8,960

 

Total shares reserved for future issuance

 

 

31,474

 

 

Summary of Stock Option Activity

The following table summarizes the stock option activity:

 

 

 

Outstanding Options

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

Average

 

 

 

Number of

 

 

Exercise

 

 

 

Shares

 

 

Price

 

Balance at December 31, 2016

 

 

11,845,376

 

 

$

14.44

 

Granted

 

 

4,300,621

 

 

$

16.17

 

Exercised

 

 

(1,350,605

)

 

$

8.49

 

Cancelled

 

 

(1,332,428

)

 

$

20.06

 

Balance at December 31, 2017

 

 

13,462,964

 

 

$

15.03

 

Granted

 

 

4,052,011

 

 

$

26.83

 

Exercised

 

 

(1,529,509

)

 

$

11.97

 

Cancelled

 

 

(720,859

)

 

$

17.98

 

Balance at December 31, 2018

 

 

15,264,607

 

 

$

18.33

 

Granted

 

 

4,933,480

 

 

$

24.21

 

Exercised

 

 

(1,983,221

)

 

$

11.18

 

Cancelled

 

 

(1,550,226

)

 

$

23.26

 

Balance at December 31, 2019

 

 

16,664,640

 

 

$

20.47

 

 

Schedule of Options Exercisable, Vested or Expected to Vest

 

 

 

Years Ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

Average

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Exercise

 

 

 

 

 

 

Exercise

 

 

 

 

 

 

Exercise

 

 

 

Options

 

 

Price

 

 

Options

 

 

Price

 

 

Options

 

 

Price

 

Exercisable at end of year

 

 

7,436,379

 

 

$

17.02

 

 

 

6,523,093

 

 

$

14.83

 

 

 

5,446,586

 

 

$

13.25

 

Options vested or expected to vest

 

 

15,962,432

 

 

$

20.31

 

 

 

14,449,017

 

 

$

18.11

 

 

 

12,854,571

 

 

$

14.98

 

 

Schedule of Exercise Prices And Weighted-average Remaining Contractual Lives For Options Outstanding

Exercise prices and weighted-average remaining contractual lives for the options outstanding as of December 31, 2019 were:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

Average

 

 

Weighted-

 

 

 

 

 

 

Exercise

 

 

 

 

 

 

 

 

 

Remaining

 

 

Average

 

 

 

 

 

 

Price of

 

Options

 

 

Range of

 

 

Contractual

 

 

Exercise

 

 

Options

 

 

Options

 

Outstanding

 

 

Exercise Prices

 

 

Life (in years)

 

 

Price

 

 

Exercisable

 

 

Exercisable

 

 

3,027,881

 

 

$5.20–$13.00

 

 

 

4.97

 

 

$

10.16

 

 

 

2,720,921

 

 

$

9.84

 

 

3,834,655

 

 

$13.05–$17.00

 

 

 

7.42

 

 

 

16.23

 

 

 

2,326,188

 

 

 

16.17

 

 

1,623,707

 

 

$17.05–$24.55

 

 

 

8.01

 

 

 

20.10

 

 

 

704,338

 

 

 

20.48

 

 

2,336,151

 

 

 

$24.97

 

 

 

8.93

 

 

 

24.97

 

 

 

644,066

 

 

 

24.97

 

 

3,877,880

 

 

 

$25.02

 

 

 

9.95

 

 

 

25.02

 

 

 

 

 

 

 

 

1,940,366

 

 

$25.06–$38.75

 

 

 

7.58

 

 

 

30.48

 

 

 

1,032,365

 

 

 

30.38

 

 

24,000

 

 

 

$39.00

 

 

 

8.56

 

 

 

39.00

 

 

 

8,501

 

 

 

39.00

 

 

16,664,640

 

 

 

 

 

 

 

7.58

 

 

 

20.47

 

 

 

7,436,379

 

 

 

17.02

 

 

Summary of Stock-Based Compensation Expense related to Stock-Based Payment Awards Granted

The following table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements (in thousands):

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Research and development

 

$

19,202

 

 

$

13,689

 

 

$

11,312

 

General and administrative

 

 

13,564

 

 

 

9,630

 

 

 

9,469

 

Sales and marketing

 

 

18,645

 

 

 

10,048

 

 

 

9,757

 

Total stock-based compensation expense

 

$

51,411

 

 

$

33,367

 

 

$

30,538

 

 

Summary of Fair Value of Option Grant and ESPP Purchase Right on Grant Date Using Black-Scholes Option Pricing Model

We estimated the fair value of each option grant and ESPP purchase right on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:

Options:

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Risk-free interest rate

 

 

1.8

%

 

 

2.8

%

 

 

2.1

%

Dividend yield

 

 

%

 

 

%

 

 

%

Volatility

 

 

66.5

%

 

 

70.4

%

 

 

74.0

%

Expected life (years)

 

 

6

 

 

 

6

 

 

 

6

 

 

ESPP:

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Risk-free interest rate

 

 

1.9

%

 

 

2.4

%

 

 

1.2

%

Dividend yield

 

 

%

 

 

%

 

 

%

Volatility

 

 

52.1

%

 

 

59.7

%

 

 

50.0

%

Expected life (months)

 

 

6

 

 

 

6

 

 

 

6